INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

As noted in Item5.07 below, at the 2017 Annual Meeting of
Shareholders (the Annual Meeting) of Intrexon Corporation (the
Company), upon recommendation of the Board of Directors of the
Company, the Companys shareholders approved an amendment (the
Amendment) to the Companys Amended and Restated 2013 Omnibus
Incentive Plan, as amended (the Plan), which provides for the
issuance of an additional two million shares of the Companys
common stock under the Plan.

A description of the Amendment is set forth on pages 75 through
77 of the definitive Proxy Statement on Schedule 14A for the 2017
Annual Meeting that was filed with the Securities and Exchange
Commission on May1, 2017, which description is incorporated by
reference herein. The description of the Amendment is qualified
in its entirety by reference to the full text of the Amendment
which is attached as Exhibit 10.1 to this Current Report on Form
8-K and which is incorporated by reference herein.

Item5.07

Submission of Matters to a Vote of Security Holders.

On June28, 2017, the Company held its 2017 Annual Meeting. At the
2017 Annual Meeting, the Companys shareholders (i)elected each of
the persons listed below as a director for a one-year term,
(ii)ratified the appointment of PricewaterhouseCoopers LLP as the
Companys independent registered accounting firm for the fiscal
year ending December31, 2017, (iii)approved a non-binding
advisory resolution approving the compensation of the named
executive officers, and (iv)approved the Amendment.

Proposal 1 Election of Directors

		For			Against			Abstain			BrokerNon-Votes
Randal J. Kirk			83,591,573				468,397				48,632				24,099,490
Cesar L. Alvarez			77,535,853				6,506,663				66,086				24,099,490
Steven R. Frank			83,444,798				597,491				66,313				24,099,490
Vinita D. Gupta			83,702,464				340,515				65,623				24,099,490
Fred Hassan			83,707,323				336,478				64,801				24,099,490
Jeffrey B. Kindler			80,619,962				3,425,321				63,319				24,099,490
Dean J. Mitchell			83,672,112				371,198				65,292				24,099,490
Robert B. Shapiro			83,658,282				386,216				64,104				24,099,490
James S. Turley			81,134,554				2,910,501				63,547				24,099,490

Proposal 2 Ratification of Appointment of
PricewaterhouseCoopers LLP as the Companys Independent Registered
Public Accounting Firm for the year ended December31, 2017

For		Against		Abstain		BrokerNon-Votes
107,883,559		202,046		122,487

Proposal 3 Non-binding Advisory Resolution
Approving the Compensation of the Named Executive Officers

For		Against		Abstain		BrokerNon-Votes
81,613,815		2,205,736		289,051		24,099,490

Proposal 4 Approval of the Amendment to the
Amended and Restated Intrexon Corporation 2013 Omnibus Incentive
Plan

For		Against		Abstain		BrokerNon-Votes
79,589,033		4,345,758		173,811		24,099,490

2

Item9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

See the Exhibit Index immediately following the page hereto,
which is incorporated herein by reference.

3

INTREXON CORP ExhibitEX-10.1 2 d419065dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Amendment to the Intrexon Corporation 2013 Omnibus Incentive Plan,…To view the full exhibit click here About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.